APA (7th ed.) Citation

A, A., F, M., EE, C., A, G., J, C., M, S., . . . A, M. (2025). Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study. Drugs - real world outcomes, 12(4), 655. https://doi.org/10.1007/s40801-025-00525-7

Chicago Style (17th ed.) Citation

A, Agiro, Mu F, Cook EE, Greatsinger A, Chen J, Sundar M, Zhao A, Colman E, and Malhotra A. "Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study." Drugs - Real World Outcomes 12, no. 4 (2025): 655. https://doi.org/10.1007/s40801-025-00525-7.

MLA (9th ed.) Citation

A, Agiro, et al. "Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study." Drugs - Real World Outcomes, vol. 12, no. 4, 2025, p. 655, https://doi.org/10.1007/s40801-025-00525-7.